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Abstract
OBJECTIVES: The incidence of surgical site infection (SSI) after open vein harvesting in coronary artery bypass grafting (CABG) patients
ranges in different studies between 2 and 20%. Triclosan is an antibacterial substance that reduces the growth of bacteria by inhibiting
fatty acid synthesis. We hypothesized that wound closure with triclosan-coated sutures would reduce SSI after open vein harvesting.
METHODS: An investigator-initiated prospective randomized double-blind single-centre study was performed with 374 patients, rando-
mized to subcutaneous and intracutaneous leg-wound closure with either triclosan-coated sutures (Vicryl Plus® and Monocryl Plus®,
Ethicon, Somerville, NJ, USA) (n = 184) or identical sutures without triclosan (n = 190) from the same manufacturer. All patients were
followed up after 30 days (clinical visit) and 60 days (telephone interview). Primary endpoint was SSI within 60 days after surgery
according to the definition of Center for Disease Control. Predefined secondary endpoints included culture-proven and antibiotic-
treated SSI.
RESULTS: The primary endpoint occurred in 23 patients (12.5%) with triclosan-coated sutures and in 38 patients (20.0%) in the group
without triclosan (P = 0.0497, risk ratio 0.63, (95% confidence interval 0.39–1.00). Corresponding figures for culture-proven infections
were 7.6 vs 12.1%, (P = 0.15), and for antibiotic-treated infections, 10.9 vs 18.4%, (P = 0.039). Staphylococcus aureus and coagulase-
negative staphylococci were the most common pathogens in both groups. Insulin-treated diabetes and vein-harvesting time were
associated with SSI after vein harvesting.
CONCLUSIONS: Leg-wound closure with triclosan-coated sutures in CABG patients reduces SSIs after open vein harvesting.
(ClinicalTrials.gov number NCT01212315).
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INTRODUCTION
Coronary artery bypass grafting (CABG) is the recommended
treatment for coronary artery disease-patients with multivessel
disease and/or left main stenosis [1]. Patients may receive a com-
bination of arterial and venous grafts. The venous graft is most
often a segment of the great saphenous vein, harvested either
with an open approach using longitudinal skin incision over the
vein, or with an endoscopic technique.
Surgical site infections (SSI) after vein harvesting are among
the most common complications in CABG patients, and these
infections are troublesome for the patients and associated with
high costs for the health-care system. The incidence of SSI after
vein harvesting is usually in the 5–10% range, however, rates
from 2 to 20% have been reported in different studies [2–4].
The large variation in incidence between studies can at least
partly be explained by wide differences in the definition of SSI
and the length of the observation period.
A number of risk factors for SSI in cardiac-surgery patients
have previously been reported, including advanced age, female
gender, hypertension, diabetes, obesity and long operation time
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[3, 4]. Another factor that may influence the incidence of SSI in
CABG patients is the suture used for closure of the wound, since
bacteria may adhere to the suture material [5]. Sutures can
be coated with antibacterial substances that may reduce the
bacterial load in the wound. Triclosan (2,4,4-trichloro-2-hydroxy-
diphenylether) is an antibacterial substance that, in preclinical
studies, has been shown to reduce the growth of bacteria by
inhibiting fatty acid synthesis [6]. Triclosan has been used in
topical preparations for antibacterial purposes. Furthermore,
triclosan-coated sutures are commercially available and have
been clinically tested in different surgical procedures with diver-
ging results [7–16]. One randomized controlled trial, comparing
triclosan-coated sutures with identical sutures without coating in
CABG patients, failed to demonstrate a difference in the inci-
dence of leg-wound SSI [13].
Based on previous clinical and preclinical studies, we hypothe-
sized that wound closure with sutures coated with triclosan
would reduce SSI after open vein harvesting. We, therefore, con-
ducted a prospective randomized double-blind single-centre
trial to test this hypothesis.
MATERIALS AND METHODS
Patients
Patients planned for CABG, CABG + aortic valve replacement (AVR)
or CABG +mitral valve repair or replacement at Sahlgrenska
University Hospital with the intended use of a saphenous vein
graft, were included in the study between March 2009 and
February 2012. All patients gave informed written consent before
inclusion in the study. Exclusion criteria were on-going sepsis or
septicaemia, on-going bacterial infections or antibiotic treatment,
participation in other clinical studies, other severe disease that
might influence wound healing, emergency surgery or known
allergy to triclosan. The study was approved by the Research Ethics
Committee at University of Gothenburg and externally monitored.
Patient characteristics and perioperative data were prospect-
ively registered in an electronic database. Samples for preopera-
tive laboratory analyses (haemoglobin, white blood cell count,
platelet count, serum-creatinine and plasma-glucose) were col-
lected the day before surgery and analysed with clinical standard
methods.
Surgical procedure
All patients were operated on with the standard technique for
CABG or CABG and valve surgery. All operations were performed
on cardiopulmonary bypass (CPB) in normothermia (35–36°C)
and with cold intermittent blood cardioplegia. All patients
received antibacterial prophylaxis with four parenteral doses of
cloxacillin 2 g. The first dose was administered 30 min before
skin incision, the second 2 h after the first dose and the follow-
ing doses 6 and 24 h later. Patients with allergy to cloxacillin
received clindamycin.
The saphenous vein segment was harvested with an open sur-
gical approach. The great saphenous vein was identified via a in-
cision 1–2 cm above the medial malleolus, and then a single
longitudinal skin incision was performed along the vein, the vein
was dissected cautiously and all side branches were ligated or
clipped. The wound was closed with one subcutaneous
continuous suture and one continuous intracutaneous suture.
The wound was covered with drape, compresses and elastic ban-
dages. The drape was removed on the fourth postoperative day.
Randomization
The patients were randomized to wound closure with triclosan-
coated sutures or sutures without triclosan. In the triclosan group,
the wound was closed subcutaneously with a 3.0 monofilament
polyglactin suture coated with triclosan (Vicryl Plus®, Ethicon, Inc.,)
and intracutaneously with a 4.0 triclosan-coated monofilament
polyglecaprone suture (Monocryl Plus®, Ethicon, Inc.). In the
no-triclosan group, identical sutures from the same manufacturer
without triclosan were used (Vicryl® and Monocryl®). The random-
ization sequence was performed with sealed envelopes. The
patients were block randomized with 25 patients randomized to
triclosan-coated sutures and 25 to no-triclosan sutures in each
block. The randomization was stratified for diabetes. A research
nurse who was not involved in the patients’ follow-up opened the
randomization envelope and delivered the sutures to the operat-
ing room. Both the coated and non-coated sutures that looked
identical were taken from their packages and put on the assist
table without any identification marks before the operating sur-
geons arrived at the operating room.
Follow-up
All wounds were inspected by a specially trained research nurse
at 4 and 30 days after surgery and evaluated according to both
the ASEPSIS score and the Centre for Disease Control (CDC) def-
inition of SSI (see below). At 60 days postoperatively, the patients
were interviewed by telephone by the same research nurse,
following a structured question form. All the research nurses
involved in the follow-up of the patients were blinded to group
allocation. If a patient reported any type of wound healing
problems including dehiscence, swelling, redness or exudate,
they were seen at the outpatient clinic, and the wounds were
evaluated and patient records were collected. Bacterial cultures
were only collected from patients with symptoms of infection,
i.e. no surveillance cultures were collected.
Outcome variables
The primary endpoint was SSI in the vein-harvesting leg, accord-
ing to CDC’s definition, within 60 days after surgery [17].
According to this definition, a superficial SSI must have at least
one of the following features: (i) purulent drainage; (ii) positive
culture; (iii) pain, tenderness, swelling, redness and deliberately
opened incision by surgeon and culture proven or not cultured
and (iv) Infection diagnosis by physician. Furthermore, a deep
SSI had to involve fascia or muscle layers.
Predefined secondary endpoints were (i) culture-proven SSI
according to CDC’s definition within 60 days after surgery; (ii)
antibiotic-treated SSI according to CDC’s definition within 60
days after surgery; (iii) ASEPSIS score at Days 30 and 60 post-
operatively; (iv) non-infectious leg-wound dehiscence within 60
days after surgery.
When using the ASEPSIS score [18], the wound is evaluated in
seven dimensions: A = additional treatment with antibiotics
L. Thimour-Bergström et al. / European Journal of Cardio-Thoracic Surgery932
(10 points), debridement (10 points) with purulent drainage
(5 points); S = serous discharge (0–5 points); E = erythema
(0–5 points); P = purulent exudates (0–10 points); S = separation
of deep tissues (0–10 points); I = isolation of bacteria (10 points);
S = stay in hospital >14 days (5 points). A score 0–10 indicates no
infection, 11–20 disturbance of healing, 21–30 minor infection,
31–40 moderate infection and >40 points severe infection [18].
Two independent observers (L.T.B. and A.J.) classified all
wound problems according to the CDC’s definition before the
randomization code was broken. Disagreement in wound evalu-
ation was solved by consensus.
Statistics
Data are presented as mean ± standard deviation, median and
range or number and percentage. A P-value of <0.05 was consid-
ered statistically significant. The power analysis of developing a
harvest-leg SSI was based on a pilot study performed at our insti-
tution (infection rate 20%) together with a literature review. Our
analysis with 80% power and a P-value of 0.05 showed it was
necessary to include 180 patients in each group to demonstrate a
50% reduction in a leg-wound infection according to the CDC
definition (primary endpoint) in one of the groups. Data were
analysed according to the ‘as treated’ principle (predefined).
The groups were compared with unpaired t-test (continuous
normally distributed data), Mann–Whitney test (continuous data
not normally distributed) or χ2test (categorical variables). The
effect of type of suture on SSI was evaluated with the χ2 test and
reported with risk ratio (RR) with 95% confidence interval (CI).
The temporal distribution of the primary endpoint was com-
pared with the log-rank test, including 5 patients who were lost
at the last follow-up. All calculations were performed on the
Statistica 10 software (StatSoft, Tulsa, OK, USA).
RESULTS
Patients
Included in the study were 392 CABG patients with the intended
use of a saphenous vein graft. A flow chart of the patients is
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shown in Fig. 1. The statistical analysis was based on 374
patients, 304 males (81%) and 70 females (19%) with a mean age
of 67 ± 8 years. Patient demographics are presented in Table 1
and perioperative variables are given in Table 2.
Infections
SSI as defined by CDC (primary endpoint) occurred in 23
patients (12.5%) in the triclosan group and in 38 (20.0%) in the
no-triclosan group, P = 0.0497. RR was 0.63 (95% CI 0.39–1.00),
as given in Table 3. The temporal distribution of the primary
endpoint is demonstrated in Fig. 2. The predefined secondary
endpoint culture-verified SSI occurred in 14 of the patients in
the triclosan group (7.6%) and in 23 of those (12.1%) in the
no-triclosan group, P = 0.145 [RR 0.63 (95% CI 0.33–1.18)]. The
predefined secondary endpoint antibiotic-treated SSI occurred
in 20 (10.9%) vs 35 (18.4%) patients, P = 0.039 [RR 0.59 (95% CI
0.35–0.98)]. ASEPSIS score tended to be lower in the triclosan
group, both at 30 and 60 days after surgery, but the difference
did not reach statistical significance, Table 3.
Patients with infection vs no-infection
Patient demographics for patients with and without harvest-leg
SSI as defined by CDC are reported in Table 4. Insulin-treated
diabetes mellitus was the only statistically different preoperative
variable with a 2-fold-higher prevalence in the infection group
(P = 0.029). Perioperative variables are reported in Table 5.
Number of distal anastomoses was higher (P = 0.014) and vein-
harvesting time was longer in patients with SSI (P < 0.001).
Microbiological agents
In total, 45 wound cultures were obtained, 16 from patients in
the triclosan group and 29 from the no-triclosan group. In the
triclosan group, 88% of the cultures were positive and 79% in
the no-triclosan group. The most common pathogen in both
groups of patients was Staphylococcus aureus, followed by
coagulase-negative staphylococci. A complete list of the cultured
microorganisms is given in Supplementary Table 1.
DISCUSSION
The main finding of this prospective randomized double-blind
study was that triclosan-coated sutures significantly reduced SSIs
after open vein harvesting in CABG patients.
Preclinical studies have shown that triclosan-coated sutures
reduce the growth of Gram-positive bacteria, e.g. S. aureus and
coagulase-negative staphylococci, and Gram-negative bacteria,
e.g. Pseudomonas aeruginosa and Escherichia coli [19, 20]. These
studies have been followed by both non-randomized retrospect-
ive studies and prospective controlled trials in different surgical
populations to test if triclosan-coated sutures reduce SSIs.
However, the results have been conflicting. Rozelle et al. [12]
reported reduced incidence of infections with triclosan-coated
sutures in wound closure for cerebrospinal fluid shunts in a pro-
spective randomized trial, and Justinger and co-workers reported
similar results from two non-randomized studies after abdominal
surgery [10, 11]. Furthermore, Galal et al. [8] reported a reduced
infection rate in a prospective randomized study in mixed surgi-
cal patients. On the other hand, Baracs et al. [7] found no differ-
ence in infection incidence in a randomized controlled trial in
abdominal surgery, and both Williams et al. [16] and Turtianien
et al. [15] reported the same outcome after breast-cancer
surgery and lower-limb vascular surgery, respectively. In cardiac-
surgery patients, Stadler et al. [14] found no difference in sternal
wound infection in a retrospective study and in a randomized
study, Isik et al. [9] found no difference in either sternal wound
or leg-wound infections. In a recent systematic review and
meta-analysis of randomized trials with triclosan-coated sutures,
Chang et al. [21] concluded that triclosan-impregnated sutures
do not decrease the rate of SSI, but also pointed out that the
quality of the studies were moderate and further high-quality in-
dependent studies are required.
In the only previously published prospective randomized trial
with triclosan-coated sutures focussing on leg-wound infections
after vein harvesting in CABG patients, Seim et al. [13] could not
identify any difference in SSI rates. The different findings from
our study could be related to several factors. Seim’s study was
not blinded and outcome measures were based on self-reports
Table 1: Patient demographics in the triclosan and
no-triclosan group
Triclosan No triclosan P-value
N 184 190
Mean age (year) 67.6 ± 8.3 66.9 ± 8.1 0.45
Female sex 39 (21.1) 31 (16.3) 0.23
BMI 27.6 ± 4.1 27.6 ± 4.1 0.67
Diabetes
No 138 (75.0) 140 (73.7) 0.77
Insulin treatment 22 (11.9) 21 (11.1) 0.78
Oral treatment 20 (10.8) 22 (11.6) 0.83
Dietary treatment 4 (2.2) 7 (3.7) 0.38
Smoking
Never 70 (38.0) 74 (38.9) 0.86
Previous (>1 month ago) 82 (44.5) 82 (43.2) 0.78
On-going 29 (15.8) 31 (16.3) 0.88
Missing 3 (1.6) 3 (1.6) 0.91
Mean EuroSCORE 4.0 ± 2.0 3.7 ± 2.2 0.15
Angina type
Unstable 88 (47.8) 95 (50.0) 0.67
Stable 90 (48.9) 93 (48.9) 0.60
No angina 6 (3.3) 2 (1.1) 0.12
Peripheral artery disease 16 (8.7) 16 (8.4) 0.92
Preoperative medication
Acetylsalicylic acid 172 (93.5) 178 (93.7) 0.98
Clopidogrel 70 (38.0) 72 (37.8) 0.92
Beta-blocker 160 (87.0) 166 (87.4) 0.97
ACE-inhibitor 106 (57.6) 120 (63.1) 0.24
Corticosteroids 8 (4.3) 6 (3.2) 0.54
Preoperative laboratory analyses
Haemoglobin (g/l) 138 ± 13 140 ± 14 0.33
White blood cell count
(×109/l)
7.6 ± 1.8 7.6 ± 1.8 0.87
Platelet count (×109/l) 270 ± 80 267 ± 71 0.67
Serum creatinine (µmol/l) 85 ± 23 86 ± 22 0.48
Plasma-glucose (mmol/l) 7.1 ± 2.8 7.0 ± 2.7 0.99
Mean ± standard deviation or number (%).
ACE: angiotensin converting enzyme; BMI: body mass index.
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from the patients, not on a structured follow-up with trained
observers blinded to group assignment. Finally, and perhaps
most importantly, the length of the follow-up differed in these
two studies. In Seim et al.’s study, the follow-up was restricted to
30 days while in the present study, the final follow-up occurred
60 days after surgery. Our decision to follow the patients for 60
days was based on a previous study from Swenne et al. [4] where
27% of the leg-wound infections were diagnosed between 30
and 60 days after surgery and a study from Jonkers et al. [22]
where 37% of leg-wound infections were diagnosed after 30
days. These results were confirmed in the present study where
19/61 of the leg-wound infections (31%) were diagnosed
between postoperative days 30 and 60 (Fig. 2).
Our extended follow-up may also, at least partially, explain the
high incidence of leg-wound SSI in the present study. The inci-
dence of SSI ranges in different studies between 2 and 20% de-
pending on definition, the follow-up time, system of reporting
infections and design of the study [2–4]. It is well known that the
rate of complications is higher in prospective trials with manda-
tory follow-up than in retrospective studies. However, the high
incidence of SSI is troublesome, and new methods and measures
are warranted to reduce its incidence. One possibility is to use
Table 2: Perioperative characteristics in the triclosan and no-triclosan group
Triclosan No-triclosan P-value
Operation
CABG 164 (89.1) 167 (87.9) 0.71
CABG + AVR 17 (9.2) 22 (11.6) 0.46
CABG +mitral repair 3 (1.6) 1 (0.5) 0.30
Number of bypasses 3.0 ± 0.9 3.2 ± 1.0 0.008
Operation time (min)
Total 181 ± 51 185 ± 54 0.41
CPB 80 ± 31 84 ± 33 0.30
Aortic clamping 52 ± 25 55 ± 26 0.33
Vein harvesting 52 ± 21 51 ± 23 0.83
Length of leg incision (cm) 43 ± 14 44 ± 14 0.62
Person harvesting the vein
Surgeon 78 (42.4) 92 (48.4) 0.24
Surgical trainee 106 (57.6) 98 (51.6) 0.24
Postoperative bleeding (ml/12 h) 470 (95–1950) 482 (110–4550) 0.94
Transfusions (units)
Packed red cells 0 (0–15) 0 (0–20) 0.73
Plasma 0 (0–9) 0 (0–20) 0.54
Platelets 0 (0–6) 0 (0–13) 0.25
Haemoglobin at discharge (g/l) 101 ± 11 102 ± 11 0.49
Mean ± standard deviation, median and range, or number (%).
AVR: aortic valve replacement; CABG: coronary artery bypass grafting; CPB: cardiopulmonary bypass.








CDC criteria 23 (12.5) 38 (20.0) 0.050
Culture proven 14 (7.6) 23 (12.1) 0.15
Antibiotic-treated 20 (10.9) 35 (18.4) 0.039
Wound dehiscence
(non-infectious)
11/161 (6.8) 13/152 (8.5) 0.57
ASEPSIS score, day 4
Mean and SD 0.4 ± 1.2 0.3 ± 0.8 0.44
Median and range 0 (0–12) 0 (0–5) 0.78
ASEPSIS score, day 30
Mean and SD 3.0 ± 7.6 4.7 ± 9.4 0.070
Median and range 0 (0–45) 0 (0–43) 0.20
ASEPSIS score, day 60
Mean and SD 3.7 ± 8.7 5.4 ± 10.0 0.097
Median and range 0 (0–45) 0 (0–43) 0.46
Mean ± standard deviation, median and range or number (%).
CDC: Centre for Disease Control; SD: standard deviation.
Figure 2: Cumulative freedom from leg-wound SSI in the triclosan group and
the no-triclosan group. T: triclosan, nT: No triclosan. Also patients lost at the
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endoscopic vein harvesting, as this has been shown to lower the
risk of wound infections in comparison to open conventional
techniques [23]. Of the known risk factors for SSI after vein har-
vesting, only insulin-treated diabetes mellitus was associated
with SSI in the present study. In addition, vein-harvesting time
emerged as a risk factor for SSI. The association between vein-
harvesting time and SSI remained after adjustment for the ex-
perience of the assisting surgeon (data not shown) and the
length of the incision. This suggests that a more complicated
vein-harvesting procedure increases the risk for SSI. The discrep-
ancy in risk factors between different studies indicates that risk
factors for SSI in cardiac surgery may be local rather than
general.
Even though our results suggest the use of triclosan-coated
sutures in order to lower the risk for SSIs, two important aspects
of triclosan use in health care products should be discussed.
First, it has been shown that there is a risk of antimicrobial resist-
ance to triclosan, including its use in topical products (e.g. cos-
metics) where resistance to populations of S. aureus has been
reported [24]. This must be regarded as a major drawback in the
use of triclosan as resistance to antibacterial substances repre-
sents a growing problem in modern medicine. On the other
hand, if the use of conventional antibiotics in patients with SSI
can be reduced by 40% with triclosan-coated sutures, as the
results of the present study suggest, this may balance or out-
weigh the disadvantages. The second issue is the long degrad-
ation time of triclosan and the potential risk for bioaccumulation
in the environment [25].
The primary endpoint in the study had a P-value of 0.0497
when assessed with χ2 test, but 0.0516 when the Fisher’s exact
test was used, a P-value just above the commonly used statistical
threshold of 0.05. This difference between these tests is very
small (0.00186) and not clinically significant; particularly as the
cut-off P-value of 0.05 is arbitrary. Furthermore, the P-value for
the somewhat stronger secondary endpoint (antibiotic-treated
Table 4: Patient demographics in patients with and
without leg infection according to CDC’s definition
Infection No infection P-value
n 61 313
age (years) 66.6 ± 7.7 67.3 ± 8.3 0.53
Female sex 11 (18.0) 59 (18.9) 0.88
BMI 28.3 ± 4.3 27.4 ± 3.8 0.081
Diabetes
No 41 (67.2) 237 (75.7) 0.16
Insulin treatment 12 (19.7) 31 (9.9) 0.029
Oral treatment 5 (8.2) 37 (11.8) 0.41
Dietary treatment 3 (4.9) 8 (2.6) 0.32
Smoking
Never 22 (36.0) 122 (39.0) 0.67
Previous (>1 month ago) 27 (44.3) 137 (43.8) 0.94
On-going 12 (19.7) 48 (15.3) 0.40
Missing data 0 6 (1.9) 0.28
EuroSCORE 3.6 ± 1.9 3.9 ± 2.2 0.23
Peripheral artery disease 7 (11.5) 25 (8.0) 0.37
Preoperative medication
Acetylsalicylic acid 59 (96.7) 291 (93.0) 0.27
Clopidogrel 24 (39.3) 118 (37.7) 0.82
Beta-blockers 56 (91.8) 270 (86.3) 0.24
ACE-inhibitor 39 (63.9) 187 (59.7) 0.56
Corticosteroids 1 (1.6) 13 (4.2) 0.34
Preoperative laboratory analyses
Haemoglobin (g/l) 141 ± 11 139 ± 14 0.35
White blood cell count
(×109/l)
7.5 ± 1.9 7.6 ± 1.8 0.60
Platelet count (×109/l) 259 ± 66 270 ± 77 0.31
Serum creatinine (µmol/l) 87 ± 21 85 ± 22 0.58
Plasma-glucose (mmol/l) 7.1 ± 3.0 7.0 ± 2.7 0.82
Mean ± standard deviation or number (%).
ACE: angiotensin converting enzyme; BMI: body mass index;
CDC: Centre for Disease Control.
Table 5: Operative characteristics in patients with and without leg infection according to CDC’s definition
Leg infection, n = 61 No leg infection, n = 313 P-value
Operation
CABG 56 (91.8) 275 (87.9) 0.38
CABG + AVR 4 (6.6) 35 (11.2) 0.28
CABG +mitral repair 1(1.6) 3 (1.0) 0.64
Number of bypasses 3.4 ± 1.0 3.1 ± 1.0 0.014
Operation time (min)
Total 184 ± 44 183 ± 54 0.76
CPB 81 ± 26 82 ± 33 0.95
Aortic clamping 53 ± 21 53 ± 27 0.92
Vein harvesting 61 ± 32 48 ± 19 <0.001
Incision length (cm) 46 ± 12 43 ± 14 0.15
Person harvesting the vein
Surgeon 28 (45.9) 141 (45.0) 0.90
Trainee 33 (54.1) 172 (55.0) 0.90
Postoperative bleeding (ml/12 h) 430 (95–1485) 500 (140–4550) 0.050
Transfusions (units)
Red blood cells 0 (0–9) 0 (0–20) 0.072
Plasma 0 (0–8) 0 (0–20) 0.93
Platelets 0 (0–6) 0 (0–13) 0.68
Haemoglobin at discharge (g/l) 101 ± 10 102 ± 11 0.36
Mean ± standard deviation, median and range or number (%).
AVR: aortic valve replacement; CABG: coronary artery bypass grafting; CDC: Centre for Disease Control; CPB: cardiopulmonary bypass.
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CDC infection) was <0.05 both with the χ2 test (0.039) and with
Fisher’s exact test (0.042). This supports the conclusion that the
triclosan suture significantly reduces bacterial leg-wound
complications.
In conclusion, the results of the present study suggest that
triclosan-coated sutures reduce the incidence of SSI after vein
harvesting in CABG patients by 35%.
SUPPLEMENTARY MATERIAL
Supplementary material is available at EJCTS online.
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APPENDIX. CONFERENCE DISCUSSION
Dr S. Collins (Lund, Sweden): I think this is a problem that usually, as surgeons,
we don’t want to see and we don’t see because, of course, we don’t do
follow-up of more than 30 days.
I was interested in the slide where you show there was no significance in
the culture-proven infection. There was no significance between the triclosan
and the no-triclosan while in the antibiotic there was. Have you got any idea
why this can happen?
Dr Jeppson: Both these diagrams showed the same pattern, about a 40%
reduction, and we are actually balancing on the P value of 0.05. So I don’t
think you should draw any strong conclusions from just this slide. We saw,
overall, a reduction in infections.
I think the reduction in antibiotic-treated infections is interesting, because
if triclosan is not good to use because of environmental reasons and because
of the risk of antibiotic resistance, we had to balance that with a 40% reduc-
tion in the use of conventional antibiotics in these patients. I can’t say if it
ends up proving that triclosan sutures should be used, but, still, we have to
take into account that triclosan-coated sutures may reduce the use of stand-
ard antibiotics.
Dr Collins: Another question. What was your strategy when you had a leg
wound infection? For how long do you treat these patients and with which
preferred drug?
Dr Jeppsson: We use a staphylococcus antibiotic like flucloxacillin as our
first choice. I have not shown you the data today, but about 50% of all infec-
tions were caused by staphylococcus aureus and another 20% were caused by
coagulase-negative staphylococcus. So some kind of staphylococcus antibio-
tics I think should be used in these patients. If the infection is not too exten-
sive we put the patient on antibiotics and tell them to come back three days
later.
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Dr Collins: And the last question is, when you do have to open the leg,
what do you do? Do you put a VAC in it, a small VAC, or not?
Dr Jeppsson: If it is extensive, a VAC. If it is not, no VAC.
Dr Collins: So if it is beyond the knee then you place the VAC, but if it is
just a little you don’t?
Dr Jeppsson: It depends on the extension of the infection.
Dr V. Kurfirst (Ceske Budejovice, Czech Republic): Just one brief question. Do
you use any type of minimally invasive harvesting techniques, which signifi-
cantly reduce the number of wound complications?
Dr Jeppsson: This was one of the questions that I expected. We don’t use it
today, but we are actually discussing starting it. I think that is a way to reduce
infections. I think these figures in our study are scary. I mean, almost a 20%
infection rate, we have to do something about this. I think that endoscopic
vein harvesting would be one possibility. The problem is that it is expensive
and you really have to show that you can get that cost back. Don’t you agree?
Dr Kurfirst: In my department we are doing about 70% with endoscopic
and about 30% with the bridging technique. So we rarely see any infections.
Dr Jeppsson: And you follow them for 60 days?
Dr Kurfirst: Yes.
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